osimertinib
astrazeneca
['adaura', 'sclc', 'osimertinib', 'nsclc', 'aura ,(-laura)']
#adaura study: adjuvant #osimertinib provided a significant overall survival benefit among patients with resected, egfr-mutated, stage ib to iiia #nsclc. the 5-year os was 88% vs 78% (hr 0.49; p&lt;0.001). osimertinib is the first tki to show os benefit in these patients. #asco2023 
🍀 Tıbbi Onkoloji Uzmanı 🍀 ✉️ Muayenehane: Kızılırmak Mah. 1441. Cadde. MEVA İş Merkezi. No: 8/20, Çukurambar, Ankara ☎️ 0(546)5541020